NASDAQ:ARQT

Arcutis Biotherapeutics News Headlines

$28.36
+0.21 (+0.75 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.85
$28.42
50-Day Range
$24.42
$34.75
52-Week Range
$17.51
$39.85
Volume83,341 shs
Average Volume169,679 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3

Arcutis Biotherapeutics (NASDAQ ARQT) News Headlines Today

SourceHeadline
Arcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Overweight at Morgan StanleyArcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Overweight at Morgan Stanley
marketbeat.com - May 27 at 7:04 AM
Arcutis Announces Appointment of Sue-Jean Lin to Board of DirectorsArcutis Announces Appointment of Sue-Jean Lin to Board of Directors
finance.yahoo.com - June 9 at 4:08 PM
Rajvir Madan Joins Arcutis as Chief Digital and Information OfficerRajvir Madan Joins Arcutis as Chief Digital and Information Officer
finance.yahoo.com - June 1 at 7:59 AM
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $25.72Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $25.72
americanbankingnews.com - May 27 at 11:57 AM
Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded to Overweight by Morgan StanleyArcutis Biotherapeutics (NASDAQ:ARQT) Upgraded to Overweight by Morgan Stanley
americanbankingnews.com - May 27 at 8:56 AM
Arcutis Biotherapeutics (NASDAQ:ARQT) Is In A Good Position To Deliver On Growth PlansArcutis Biotherapeutics (NASDAQ:ARQT) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - May 7 at 10:05 AM
Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
finance.yahoo.com - May 6 at 1:08 PM
Arcutis Announces First Quarter 2021 Financial Results and Provides Business UpdateArcutis Announces First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 8:49 PM
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring SymposiumArcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
finance.yahoo.com - May 3 at 5:46 PM
Arcutis to Present at the 2021 Truist Securities Life Sciences SummitArcutis to Present at the 2021 Truist Securities Life Sciences Summit
finance.yahoo.com - April 28 at 6:06 PM
Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021
finance.yahoo.com - April 23 at 12:39 PM
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five YearsArcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
finance.yahoo.com - April 12 at 12:54 PM
Arcutis Biotherapeutics Enters Oversold TerritoryArcutis Biotherapeutics Enters Oversold Territory
nasdaq.com - March 29 at 2:48 PM
Arcutis Announces Updates to its Executive TeamArcutis Announces Updates to its Executive Team
finance.yahoo.com - March 26 at 9:20 AM
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for VitiligoArcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
finance.yahoo.com - March 18 at 1:23 PM
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021
finance.yahoo.com - March 17 at 7:46 PM
Arcutis Biotherapeutics Inc.Arcutis Biotherapeutics Inc.
barrons.com - March 12 at 3:52 PM
Arcutis to Present at the Cowen 41st Annual Health Care ConferenceArcutis to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - February 25 at 7:00 PM
Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of StaffCourtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff
finance.yahoo.com - February 18 at 9:26 AM
Arcutis Biotherapeutics Announces Closing of Underwriters Over-Allotment Option in Connection with Public Offering of Common StockArcutis Biotherapeutics Announces Closing of Underwriters' Over-Allotment Option in Connection with Public Offering of Common Stock
marketwatch.com - February 16 at 10:12 PM
Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateArcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - February 16 at 5:11 PM
Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common StockArcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock
finance.yahoo.com - February 16 at 12:11 PM
How Many Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Do Institutions Own?How Many Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Do Institutions Own?
finance.yahoo.com - February 6 at 8:45 AM
Arcutis Biotherapeutics, Inc. (ARQT) Upgraded to Buy: Heres WhyArcutis Biotherapeutics, Inc. (ARQT) Upgraded to Buy: Here's Why
finance.yahoo.com - February 3 at 2:07 PM
Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common StockArcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - February 2 at 11:57 PM
Arcutis Biotherapeutics Announces Proposed Public Offering of Common StockArcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 1 at 7:09 PM
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque PsoriasisArcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
finance.yahoo.com - February 1 at 9:08 AM
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic DermatitisArcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
finance.yahoo.com - January 20 at 10:16 AM
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic DermatitisArcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
finance.yahoo.com - January 13 at 10:08 AM
Matthew Moore Joins Arcutis as Chief Business OfficerMatthew Moore Joins Arcutis as Chief Business Officer
finance.yahoo.com - January 11 at 1:35 PM
Arcutis Biotherapeutics Added to Nasdaq Biotechnology IndexArcutis Biotherapeutics Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 21 at 1:59 PM
Arcutis Biotherapeutics IncArcutis Biotherapeutics Inc
bloomberg.com - December 17 at 12:02 AM
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day onArcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on
bloomberg.com - December 12 at 12:17 AM
Is ARQT A Good Stock To Buy Now?Is ARQT A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 1:28 AM
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020
finance.yahoo.com - December 9 at 1:37 PM
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisArcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
finance.yahoo.com - December 7 at 6:11 PM
Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020
finance.yahoo.com - December 2 at 5:57 PM
Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisData from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
finance.yahoo.com - December 1 at 4:26 PM
Arcutis Bio soars 17% on promising roflumilast foam data for scalp and body psoriasisArcutis Bio soars 17% on promising roflumilast foam data for scalp and body psoriasis
seekingalpha.com - November 23 at 1:20 PM
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body PsoriasisArcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis
finance.yahoo.com - November 23 at 8:20 AM
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceArcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 11 at 7:56 PM
Arcutis Announces Third Quarter 2020 Financial Results and Provides Business UpdateArcutis Announces Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 5 at 9:08 PM
Arcutis Announces Appointment of Terrie Curran to Board of DirectorsArcutis Announces Appointment of Terrie Curran to Board of Directors
finance.yahoo.com - November 4 at 5:41 PM
Arcutis Bio topical cream achieves secondary endpoints in mid-stage psoriasis and dermatitis studiesArcutis Bio topical cream achieves secondary endpoints in mid-stage psoriasis and dermatitis studies
seekingalpha.com - November 2 at 12:47 PM
Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic DermatitisArcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis
finance.yahoo.com - November 2 at 12:47 PM
Arcutis Biotherapeutics: Interesting, But Needs Cautious Approach HereArcutis Biotherapeutics: Interesting, But Needs Cautious Approach Here
seekingalpha.com - October 31 at 5:40 PM
Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology ConferencesArcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences
finance.yahoo.com - October 29 at 11:15 PM
Arcutis Completes Enrollment in Phase 1/2b Study Evaluating  ARQ-252 in Chronic Hand EczemaArcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
finance.yahoo.com - October 26 at 10:19 AM
Benzingas Top Upgrades, Downgrades For October 8, 2020Benzinga's Top Upgrades, Downgrades For October 8, 2020
finance.yahoo.com - October 12 at 7:26 AM
Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisArcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
finance.yahoo.com - September 16 at 9:24 AM
Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020
finance.yahoo.com - September 15 at 9:33 AM
This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.